Effects of semaglutide and tirzepatide on blood vessels and the heart
Tests how semaglutide and tirzepatide affect blood vessels and the heart in adults.
Plain-language title generated from the registry record
Registry title: DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
Key facts
- Where
- Cambridge, United KingdomSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07483801, who can take part
Where in United Kingdom
- Addenbrooke's HospitalCambridge, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cambridge University Hospitals NHS Foundation Trust
- Trial code
- NCT07483801
- Record updated
- 19 March 2026
- Original description
What is the research question? Semaglutide and tirzepatide cause weight loss and blood pressure reduction. However, weight loss only partially explains the blood pressure reduction. Based on previous studies, there might be direct effects in the cardiovascular system. In forearm blood flow studies, semaglutide and tirzepatide will be infused into the brachial artery to investigate their effects on the function of blood vessels. In systemic studies, semaglutide and tirzepatide will be infused into systemic circulation to investigate their effects on heart and blood vessels.Read full original descriptionShow less
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
What is the research question? Semaglutide and tirzepatide cause weight loss and blood pressure reduction. However, weight loss only partially explains the blood pressure reduction. Based on previous studies, there might be direct effects in the cardiovascular system. In forearm blood flow studies, semaglutide and tirzepatide will be infused into the brachial artery to investigate their effects on the function of blood vessels. In systemic studies, semaglutide and tirzepatide will be infused into systemic circulation to investigate their effects on heart and blood vessels.
There are three different populations being looked at for this study: participants with normal weight and normal blood pressure, participants with obesity and normal blood pressure, and participants with obesity and high blood pressure.
There are six sub-studies each with different visit schedules. The minimum participant study duration (including follow-up phone call) would be 2 days, while the maximum participant study duration would be approximately 2 - 2.5 months. The overall study duration is expected to be approximately 18 months.
Inclusion: Inclusion Criteria - Participants with normal weight and normal blood pressure; Have given written informed consent to participate; Aged 18 to 50 years (inclusive); Females must be post/peri-menopausal or if of child-bearing potential they are required to use adequate contraception and to have a negative pregnancy test (performed at each visit); Current non-smoker; Body mass index (BMI) in range 18.5-24.9 kg/m2; Clinic brachial systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg; Inclusion Criteria - Obese participants with normal blood pressure; Have given written informed consent to participate; Aged 18 to 50 years (inclusive); Male or female; Females must be post/peri-menopausal or if of child-bearing potential they are required to use adequate contraception and to have negative pregnancy test (performed at each visit); Current non-smoker; BMI ≥30 kg/m2; Clinic brachial systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg; Inclusion Criteria - Obese participants with high blood pressure; Have given written informed consent to participate; Aged 18 to 50 years (inclusive); Male or female; Females must be post/peri-menopausal or if of child-bearing potential they are required to use adequate contraception and to have negative pregnancy test (performed at each visit); Current non-smoker; BMI ≥30 kg/m2; Diagnosis of stage 1 essential hypertension.
Exclusion: Participants treated with formal anticoagulant therapy such as, but not limited to, heparin or warfarin; Currently taking drugs likely to have interactions with semaglutide or tirzepatide; Regular use of medications with vasoactive or cardiac effects in normotensive individuals; inability or unwillingness to omit anti-hypertensive medications on the morning of the study visits in hypertensive individuals; Hypersensitivity to any of the study drugs or excipients; Known clinically significant valvular heart disease; Known active malignancy; Clinically significant neurological disease; History of scleroderma; Second or third-degree AV block, sino-atrial block, sick sinus syndrome; Known HIV, hepatitis B or C; Diagnosis of Type 1 or Type 2 Diabetes Mellitus or current usage of insulin or other injectable drugs for the treatment of diabetes such as but not limited to GLP-1 and GIP receptor agonists; Known heart failure; Family history of multiple endocrine neoplasia; Known thyroid cancer; Known history of pancreatitis; History of gall stones (unless the gall bladder has been removed); Known renal impairment (creatinine >150µmol/L); Implanted pacemaker or implantable cardioverter defibrillator (ICD); Current pregnancy, breastfeeding; Current involvement in the active treatment phase of other research studies (excluding observational/non-interventional); Needle phobia; BMI <18.5 kg/m2; Any other clinical reason which may preclude entry in the opinion of the investigator.